Shattuck Labs vs Yarrow Bioscience
STTK and YARW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How STTK and YARW compare
Shattuck Labs is the larger company, worth 11 times as much as Yarrow Bioscience ($507M against $48.2M).
Yarrow Bioscience grew revenue faster over the last twelve months (13.8% versus −100% for Shattuck Labs).
Yarrow Bioscience pays a dividend yielding 111%; Shattuck Labs does not pay one.
Yarrow Bioscience scores higher on the StockData Score (11 against 8 for Shattuck Labs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | STTK | YARW |
|---|---|---|
| Size and price | ||
| Market cap | $507M | $48.2M |
| Share price | $5.05 | $18.05 |
| Change, 1 year | 167% | −0.55% |
| Change, 5 years | −46.3% | −98.1% |
| Beta (5Y) | 1.63 | 1.55 |
| Employees | 40 | 10 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/S | – | 84.5× |
| P/B | 2.6× | 2.2× (better) |
| FCF yield | – | −68.7% |
| Fair value | – | $7.33 |
| Margin of safety | – | −146% |
| Growth | ||
| Revenue growth (TTM) | −100% | 13.8% (better) |
| Revenue growth, 5Y average | −36.8% (better) | −51.4% |
| Profitability | ||
| Operating margin | – | −5219% |
| Net margin | – | −4646% |
| FCF margin | – | −5811% |
| Return on equity | −47.2% (better) | −86.9% |
| Return on invested capital | −2531% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 15.80 (better) | 15.26 |
| Altman Z-score | 17.92 (better) | −29.60 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 111% |
| Buyback yield | −19.9% | – |
| Shareholder yield | −19.9% | 111% (better) |
| Ownership | ||
| Held by institutions | 83.5% | 11.6% |
| Held by insiders | 24.1% | 82.1% |
| Insider net buying, 12 months | −$342K | – |
| Short interest, % of float | 14.1% | 29.7% |
Go deeper
- STTK stock overview
- STTK income statement
- STTK valuation and score
- YARW stock overview
- YARW income statement
- YARW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.